` 4523 (Eisai Co Ltd) vs Nikkei 225 Comparison - Alpha Spread

4523
vs
Nikkei 225

Over the past 12 months, has underperformed Nikkei 225, delivering a return of -35% compared to the Nikkei 225's 7% drop.

Stocks Performance
4523 vs Nikkei 225

Loading
4523
Nikkei 225
Add Stock

Performance Gap
4523 vs Nikkei 225

Sign Up to see
Performance Gap
Sign In
Sign Up

Performance By Year
4523 vs Nikkei 225

Loading
4523
Nikkei 225
Add Stock

Competitors Performance
Eisai Co Ltd vs Peers

Nikkei 225
4523
LLY
JNJ
NOVO B
ROG
Add Stock

Eisai Co Ltd
Glance View

Market Cap
1.1T JPY
Industry
Pharmaceuticals

Eisai Co., Ltd., established in 1941, has emerged as a formidable player in the global pharmaceutical landscape, forging its reputation through a steadfast commitment to "human health care" (hhc). Rooted in Tokyo, the company orbits around the development of innovative treatments targeting neurology and oncology, positioning itself as a beacon of hope for patients worldwide. Eisai's journey is characterized by a persistent focus on medicinal breakthroughs in areas such as Alzheimer’s disease, liver cancer, and epilepsy—disease states that critically affect the quality of life but often have limited treatment options. Through its rigorous research and development efforts, the company crafts both small molecule drugs and biologics, distinguishing itself with flagship products like Aricept for Alzheimer's and Lenvima for cancer, both of which have cemented its reputation in the medical community and are vital streams of revenue. Eisai's business framework is intricately woven into a global tapestry of partnerships and collaborations, which amplifies its market reach and bolsters its financial performance. By strategically aligning with global pharmaceutical giants and leveraging robust patent portfolios, Eisai extends its innovative therapies to numerous markets. This strategic network allows it to not only enhance drug distribution and sales but also to engage in co-development, introducing shared stewardship in groundbreaking research. The company's financial structure is further reinforced through a diversified portfolio, inclusive of both branded prescription drugs and over-the-counter products, thus facilitating consistent cash flow and enabling ongoing investments in research. These deliberate steps underscore Eisai's pursuit of longevity in a fiercely competitive industry, ensuring it remains well-poised to continually adapt and thrive amidst evolving healthcare challenges.

Eisai Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top